Effective use of statins to prevent coronary heart disease

American Family Physician

Volumn 63, Issue 2, 2001, Pages

  Crouch, Michael A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIET; DOSE RESPONSE; DRUG COST; FEMALE; GENERAL PRACTICE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MALE; META ANALYSIS; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION;

CHOLESTEROL, LDL; CORONARY DISEASE; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LOVASTATIN; PRAVASTATIN; PYRIDINES; PYRROLES; RISK FACTORS; SIMVASTATIN;

EID: 0035862755     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. The Expert Panel
2. Cholesterol testing and management: A national comparison of family physicians, general internists, and cardiologists
3. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
6. Intensive lifestyle changes for reversal of coronary heart disease
7. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction
8. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
10. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
11. Effect of pravastatin on cardio-vascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial
12. Triglyceride as a risk factor for coronary artery disease
13. Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects
14. Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study
15. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases
16. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
17. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: Interim report
18. Measurement and management of hyperlipidemia for the primary prevention of coronary heart disease
19. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (45)
20. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
21. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with atorvastatin versus revascularization treatments (AVERT)
22. Atherosclerosis regression, plaque disruption, and cardio-vascular events: A rationale for lipid lowering in coronary artery disease
23. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease
24. Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: Absolute levels or extent of lowering?
25. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
26. Usefulness of hypertriglyceridemia in predicting myocardial infarction late after coronary artery bypass operation
27. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
28. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
29. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy
30. Cost-effectiveness of statins
31. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events
32. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations. Lipoprotein and Coronary Atherosclerosis Study (LCAS)
33. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
34. Statin trials and goals of cholesterol-lowering therapy
35. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. The CURVES study
36. A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia
37. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease
38. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients: A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin
39. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia
40. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
41. Comparison of statins in hypertriglyceridemia
42. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia
43. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
44. Persistence of use of lipid-lowering medications: A cross-national study